News
Examine the Chinese Pharmaceuticals and Healthcare Industry with this Comprehensive Report, Q3 2008
DUBLIN, Ireland-(Business Wire)-October 3, 2008 - Research and Markets (http://www.researchandmarkets.com/research/64d5f7/china_pharmaceutic) has announced the addition of the "China Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
China Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on China's pharmaceuticals and healthcare industry.
In the late 1990s and early 2000s, China's pharmaceutical sector was substantially smaller than it is today, and was dominated by acute care treatments, with the majority of sales occurring at large hospitals. As the country's economy has developed, the sector has experienced year-on-year double-digit growth as the state encouraged the sector's development. Western multinationals have increasingly formed joint ventures with local firms, and smaller domestic players have been eliminated by the imposition of improved manufacturing standards. Consequentially, BMI is forecasting strong growth for China’s pharmaceutical market, which is expected to reach a valuation of US$88.61bn by 2012.
Since May 2007, the Chinese yuan:US dollar ratio has decreased from CNY7.65:US$1 to CNY6.94:US$1, a fall of just under 10%. There are likely to be two main effects of the strengthening yuan: first that Chinese partners in joint ventures with US firms will contribute more, and second that US exports to China will increase. Given that BMI's country risk team expects the ratio to reach CNY6.70:US$1 before the end of 2008, the aforementioned trends are likely to become more pronounced throughout the year.
During Q208 and Q308, China's authorities increasingly cracked down on producers and prescribers of anabolic steroids ahead of the 2008 Olympic Games. Manufacturers of these agents have been added to a watch-list, while the Ministry of Health expects medical institutions to check the identity of patients before prescribing anabolic steroids and other hormone-containing drugs.
In July 2008 that UK-based GlaxoSmithKline (GSK) announced that it planned to double its R&D capabilities in China. At that time, the company employed 170 research staff and planned to boost this figure to 200 by the end of 2008, and to 350 the next year. It is BMI’s view that more multinationals will be following GSK’s enlightened approach.
The prevalence of obesity in China is rising fast as people add more meat and diary products to their diets and urbanisation and the associated trend of more sedentary jobs compound the problem. Latest research shows that of all the developing countries, only Mexico's growth in the proportion of the adult population who are overweight and obese is faster than that of China. Given the consequential health problems that will present over the medium term, BMI expects the frequency and intensity of healthy living campaigns in China to increase.
Key Topics Covered:
Executive Summary
China Pharmaceuticals And Healthcare Industry SWOT
China Political SWOT
China Economic SWOT
China Business Environment SWOT
Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
China: Market Summary
Regulatory Regime
Intellectual Property Issues
Counterfeit Activities
Pricing And Reimbursement
Advertising Sector
SFDA Scandal
Other Regulatory Developments
Industry Trends And Developments
Healthcare Sector
Hospital Sector
Epidemiology
Overseas Activity
Domestic Pharmaceutical Sector
Recent Developments In The Local Pharmaceutical Sector
Distribution Sector
Foreign Company Activity
Acquisitions
Traditional Chinese Medicines
R&D Activity
Vaccine Sector
Clinical Trials Activity
Biotechnology Sector
Active Pharmaceutical Ingredients (APIs)
Industry Forecast Scenario
Overall Market Forecast
Key Growth Factors – Industry
Key Growth Factors – Macroeconomic
Prescription Market Forecast
OTC Market Forecast
Generics And Patented Market Forecasts
Export/Import Forecasts
Medical Device Market Forecast
China: Medical Device Market Data And Forecasts (US$bn unless otherwise stated)
Other Healthcare Data Forecasts
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Top Ten Chinese Pharmaceutical Companies In 2007
Top Ten Chinese Retail Pharmacy Chains In 2007
Company Profiles
Leading Multinational Companies
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Industry
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Weighting
Sources
Companies Mentioned:
- GlaxoSmithKline
- Pfizer
- AstraZeneca
- Merck KGaA
- Sanofi-Aventis
- Novartis
- Roche
- Merck & Co
- Bayer Schering Pharma
For more information visit http://www.researchandmarkets.com/research/64d5f7/china_pharmaceutic
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
